ArticleFrontiers in pharmacology2020
Dual Monoclonal Antibody Therapy for a Severe Asthma Patient.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Trial
- Dual biological treatments in immune-mediated disorders: a single center experience.BMC immunology · 2025Article
- Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways.Immunological reviews · 2024Review
- Dual biologics for severe asthma and atopic dermatitis: Synopsis of two cases and literature review.Respirology case reports · 2024Article
- Evaluation of antibody drug delivery efficiency via nebulizer in various airway models and breathing patterns.BMC pharmacology & toxicology · 2023Article
- Combination of Biological Therapy in Severe Asthma: Where We Are?Journal of personalized medicine · 2023Review
- Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases.The World Allergy Organization journal · 2022Article
- Successful simultaneous targeting of IgE and IL-5 in a severe asthmatic patient selected for lung transplantation.The World Allergy Organization journal · 2022Article
- Specific Therapy for T2 Asthma.Journal of personalized medicine · 2022Review
- Cost Utility of Bronchial Thermoplasty for Severe Asthma: Implications for Future Cost-Effectiveness Analyses Based on Phenotypic Heterogeneity.ClinicoEconomics and outcomes research : CEOR · 2022Article
- [Consensus document for Severe Asthma. 2025 Update].Open respiratory archivesArticle
- [Consensus document for severe asthma in adults. 2022 update].Open respiratory archivesArticle
- Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma.Open respiratory archivesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOmalizumab, the first biological treatment for severe allergic bronchial asthma, has been on the market for more than a decade. Omalizumab was initially considered to be an IgE-blocking agent, and therefore, an inhibitor of the Th2 (allergic or adaptive) cascade. More recently, other monoclonal antibodies for severe eosinophilic asthma have become available, which exert an anti-eosinophilic effect basically by blocking IL5 or its receptor. These agents exert this effect regardless of the origin of the eosinophils (i.e., the adaptive or the innate immune system). CASE STUDY: An oral corticosteroid-dependent allergic asthma patient was treated with omalizumab. After a year of treatment, the improvement remained very limited and the medical team proposed discontinuation. However, the patient felt that her asthma had improved and she refused to give up the therapy, which continued for ten years. The mean accumulated oral corticosteroid dose per month during the last year was around 200 mg; despite this, the FEV
resultsAfter 24 months of dual therapy, a marked improvement in the FEV
conclusionsIn some severe allergic asthma patients with persistently high eosinophil counts in peripheral blood and who are considered non- or mild responders to anti-IgE and anti-IL5 administered individually, a combination of the two antibodies covering the entire T2 spectrum may be effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.